Clinical Trials

By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Learn more about ongoing, Apellis-sponsored clinical trials below.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PEGASUS Clinical Trial: A Phase 3 study to evaluate the efficacy and safety of pegcetacoplan (APL‑2) in patients with paroxysmal nocturnal hemoglobinuria

Learn More

pnhstudy.com


Study

PRINCE Clinical Trial: A Phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan (APL‑2) in patients with PNH

Learn More

clinicaltrials.gov


Study

PADDOCK Clinical Trial: Pilot study to assess safety, preliminary efficacy and pharmacokinetics of subcutaneous pegcetacoplan (APL‑2) in PNH subjects

Learn More

clinicaltrials.gov


Study

PALOMINO Clinical Trial: A Phase 2a, open-label study to evaluate the efficacy and safety of pegcetacoplan (APL‑2) in patients with PNH who have never been treated with eculizumab

Learn More

clinicaltrials.gov.


Study

PHAROAH Clinical Trial: A Phase 1 study to assess the safety of pegcetacoplan (APL‑2) as an add-on to standard of care in subjects with PNH

Learn More

clinicaltrials.gov


Study

An open-label, nonrandomized, multicenter extension study to evaluate the long term safety and efficacy of pegcetacoplan (APL‑2) in patients with PNH

Learn More

clinicaltrials.gov


Geographic Atrophy (GA)

Study

DERBY & OAKS Clinical Trials: Two Phase 3 clinical studies of pegcetacoplan (APL‑2) therapy in patients with GA

Learn More

gastudy.com


Autoimmune Hemolytic Anemia (AIHA)

Study

PLAUDIT Clinical Trial: A Phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of pegcetacoplan (APL‑2) in patients with autoimmune hemolytic anemia (AIHA).


Nephropathies

Study

DISCOVERY Clinical Trial: Phase 2 study assessing safety and efficacy of pegcetacoplan (APL‑2) in glomerulopathies